Gulati Sunita, Sastry Kedarnath, Jensenius Jens C, Rice Peter A, Ram Sanjay
Section of Infectious Diseases and Hematology-Oncology, Evans Biomedical Research Center, Boston University Medical Center, Boston, MA 02118, USA.
J Immunol. 2002 Apr 15;168(8):4078-86. doi: 10.4049/jimmunol.168.8.4078.
We examined complement activation by Neisseria gonorrhoeae via the mannan-binding lectin (MBL) pathway in normal human serum. Maximal binding of MBL complexed with MBL-associated serine proteases (MASPs) to N. gonorrhoeae was achieved at a concentration of 0.3 microg/ml. Preopsonization with MBL-MASP at concentrations as low as 0.03 microg/ml resulted in approximately 60% killing of otherwise fully serum-resistant gonococci. However, MBL-depleted serum (MBLdS) reconstituted with MBL-MASP before incubation with organisms (postopsonization) failed to kill at a 100-fold higher concentration. Preopsonized organisms showed a 1.5-fold increase in C4, a 2.5-fold increase in C3b, and an approximately 25-fold increase in factor Bb binding; enhanced C3b and factor Bb binding was classical pathway dependent. Preopsonization of bacteria with a mixture of pure C1-inhibitor and/or alpha(2)-macroglobulin added together with MBL-MASP, all at physiologic concentrations before adding MBLdS, totally reversed killing in 10% reconstituted serum. Reconstitution of MBLdS with supraphysiologic (24 microg/ml) concentrations of MBL-MASP partially overcame the effects of inhibitors (57% killing in 10% reconstituted serum). We also examined the effect of sialylation of gonococcal lipooligosaccharide (LOS) on MBL function. Partial sialylation of LOS did not decrease MBL or C4 binding but did decrease C3b binding by 50% and resulted in 80% survival in 10% serum (lacking bacteria-specific Abs) even when sialylated organisms were preopsonized with MBL. Full sialylation of LOS abolished MBL, C4, and C3b binding, resulting in 100% survival. Our studies indicate that MBL does not participate in complement activation on N. gonorrhoeae in the presence of "complete" serum that contains C1-inhibitor and alpha(2)-macroglobulin.
我们检测了淋病奈瑟菌在正常人血清中通过甘露聚糖结合凝集素(MBL)途径激活补体的情况。MBL与MBL相关丝氨酸蛋白酶(MASP)形成的复合物与淋病奈瑟菌的最大结合浓度为0.3微克/毫升。低至0.03微克/毫升浓度的MBL-MASP预调理可导致原本完全血清抗性的淋球菌约60%被杀死。然而,在与细菌孵育前(后调理)用MBL-MASP重构的MBL缺失血清(MBLdS),即使浓度高100倍也无法杀死细菌。预调理的细菌C4增加了1.5倍,C3b增加了2.5倍,Bb因子结合增加了约25倍;C3b和Bb因子结合增强依赖于经典途径。在添加MBLdS之前,将生理浓度的纯C1抑制剂和/或α2-巨球蛋白与MBL-MASP混合对细菌进行预调理,在10%重构血清中完全逆转了杀伤作用。用超生理浓度(24微克/毫升)的MBL-MASP重构MBLdS可部分克服抑制剂的作用(在10%重构血清中有57%的杀伤率)。我们还检测了淋球菌脂寡糖(LOS)的唾液酸化对MBL功能的影响。LOS部分唾液酸化并未降低MBL或C4的结合,但C3b结合降低了50%,即使唾液酸化的细菌用MBL进行预调理,在10%血清(缺乏细菌特异性抗体)中仍有80%存活。LOS完全唾液酸化消除了MBL-C4和C3b的结合,导致100%存活。我们的研究表明,在含有C1抑制剂和α2-巨球蛋白的“完全”血清存在的情况下,MBL不参与淋病奈瑟菌的补体激活。